Cuffe Michael S.

SEC source: 0001193125-26-049186 · ownership.xml · nonDerivative · entry 2

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,079.9017

SEC source: 0001193125-26-049186 · ownership.xml · nonDerivative · entry 1

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,580.9017

F1 · kind: On January 30, 2023, the reporting person was granted 4,814 performance share units. The performance share units were eligible to vest based on achievement of a cumulative earnings per share goal for fiscal years 2023-2025. The number of performance share units that were eligible to vest varied from zero (for actual performance less than 90% of target) to two times the units granted (for actual performance of 110% or more of target). Based upon the Company's achievement with respect to cumulative 2023-2025 earnings per share, the number of performance share units that vested equaled 200% of the units granted.

SEC source: 0001193125-26-039795 · ownership.xml · nonDerivative · entry 2

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,952.9017

SEC source: 0001193125-26-039795 · ownership.xml · nonDerivative · entry 1

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,002.9017

SEC source: 0001193125-26-033998 · ownership.xml · derivative · entry 1

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,067

Underlying: Common Stock · 8,067 shares

Expires 2036-01-29

F1 · derivative.exercise_date: The stock appreciation rights vest in four equal annual installments beginning on January 29, 2027.

SEC source: 0001632835-25-000003 · ownership.xml · nonDerivative · entry 3

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,502.9017

F1 · kind: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2025.

F2 · balance_after: Includes 2,595.9017 shares acquired under the Issuer's employee stock purchase plans.

SEC source: 0001632835-25-000003 · ownership.xml · derivative · entry 4

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,920 shares

Expires 2031-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2025.

F3 · derivative.exercise_date: The stock appreciation rights vested in four equal annual installments beginning on February 3, 2022.

SEC source: 0001632835-25-000003 · ownership.xml · nonDerivative · entry 2

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,338.9017

F1 · kind: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2025.

F2 · balance_after: Includes 2,595.9017 shares acquired under the Issuer's employee stock purchase plans.

SEC source: 0001632835-25-000003 · ownership.xml · nonDerivative · entry 1

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,422.9017

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2025.

F2 · balance_after: Includes 2,595.9017 shares acquired under the Issuer's employee stock purchase plans.

SEC source: 0000950170-25-022652 · ownership.xml · nonDerivative · entry 2

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,425.2085

SEC source: 0000950170-25-022652 · ownership.xml · nonDerivative · entry 1

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,008.2085

F1 · kind: On January 28, 2022, the reporting person was granted 4,490 performance share units. The performance share units were eligible to vest based on achievement of a cumulative earnings per share goal for fiscal years 2022-2024. The number of performance share units that were eligible to vest varied from zero (for actual performance less than 90% of target) to two times the units granted (for actual performance of 110% or more of target). Based upon the Company's achievement with respect to cumulative 2022-2024 earnings per share, the number of performance share units that vested equaled 51.9% of the units granted.

SEC source: 0000950170-25-011251 · ownership.xml · derivative · entry 1

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,171

Underlying: Common Stock · 11,171 shares

Expires 2035-01-28

F1 · derivative.exercise_date: The stock appreciation rights vest in four equal annual installments beginning on January 28, 2026.

SEC source: 0000950170-24-106008 · ownership.xml · nonDerivative · entry 3

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,678.2085

F1 · kind: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 7, 2024.

F2 · balance_after: Includes 2,518.2085 shares acquired under the Issuer's employee stock purchase plans.

SEC source: 0000950170-24-106008 · ownership.xml · derivative · entry 4

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,080 shares

Expires 2030-01-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 7, 2024.

F3 · derivative.exercise_date: The stock appreciation rights vested in four equal annual installments beginning on January 29, 2021.

SEC source: 0000950170-24-106008 · ownership.xml · nonDerivative · entry 2

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,036.2085

F1 · kind: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 7, 2024.

F2 · balance_after: Includes 2,518.2085 shares acquired under the Issuer's employee stock purchase plans.

SEC source: 0000950170-24-106008 · ownership.xml · nonDerivative · entry 1

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,758.2085

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 7, 2024.

F2 · balance_after: Includes 2,518.2085 shares acquired under the Issuer's employee stock purchase plans.

SEC source: 0001209191-24-005627 · doc4.xml · nonDerivative · entry 1

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,623.9692

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $316.7603 to $317.07, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-24-005570 · doc4.xml · nonDerivative · entry 4

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,934.9692

F1 · balance_after: Includes 2,463.9692 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan.

SEC source: 0001209191-24-005570 · doc4.xml · derivative · entry 5

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,660 shares

Expires 2029-01-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock appreciation rights vested in four equal annual installments beginning on January 30, 2020.

SEC source: 0001209191-24-005570 · doc4.xml · nonDerivative · entry 3

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,434.9692

F1 · balance_after: Includes 2,463.9692 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan.

SEC source: 0001209191-24-005570 · doc4.xml · nonDerivative · entry 2

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,783.9692

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 2,463.9692 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan.

SEC source: 0001209191-24-005570 · doc4.xml · nonDerivative · entry 1

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,123.9692

F1 · balance_after: Includes 2,463.9692 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan.

SEC source: 0001209191-24-003743 · doc4.xml · nonDerivative · entry 3

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,696.9672

SEC source: 0001209191-24-003743 · doc4.xml · nonDerivative · entry 2

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,908.9672

F2 · kind: On October 25, 2021, the reporting person was granted 2,210 performance share units. The performance share units were eligible to vest based on achievement of a cumulative earnings per share goal for fiscal years 2021-2023. The number of performance share units that were eligible to vest varied from zero (for actual performance less than 90% of target) to two times the units granted (for actual performance of 110% or more of target). Based upon the Company's achievement with respect to cumulative 2021-2023 earnings per share, the number of performance share units that vested equaled 200% of the units granted.

SEC source: 0001209191-24-003743 · doc4.xml · nonDerivative · entry 1

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,488.9672

F1 · kind: On February 3, 2021, the reporting person was granted 6,280 performance share units. The performance share units were eligible to vest based on achievement of a cumulative earnings per share goal for fiscal years 2021-2023. The number of performance share units that were eligible to vest varied from zero (for actual performance less than 90% of target) to two times the units granted (for actual performance of 110% or more of target). Based upon the Company's achievement with respect to cumulative 2021-2023 earnings per share, the number of performance share units that vested equaled 200% of the units granted.

SEC source: 0001209191-24-002721 · doc4.xml · derivative · entry 3

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,656

Underlying: Common Stock · 12,656 shares

Expires 2034-01-31

F2 · derivative.exercise_date: The stock appreciation rights vest in four equal annual installments beginning on January 31, 2025.

SEC source: 0001209191-24-002721 · doc4.xml · nonDerivative · entry 2

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,928.9672

F1 · balance_after: Includes 2,436.9672 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan.

SEC source: 0001209191-24-002721 · doc4.xml · nonDerivative · entry 1

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,128.9672

F1 · balance_after: Includes 2,436.9672 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan.

SEC source: 0001209191-23-026609 · doc4.xml · nonDerivative · entry 1

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,783.3569

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $284.29 to $284.95, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-23-025692 · doc4.xml · derivative · entry 3

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 32,020 shares

Expires 2028-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock appreciation rights vested in four equal annual installments beginning on January 31, 2019.

SEC source: 0001209191-23-025692 · doc4.xml · nonDerivative · entry 2

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,339.3569

F1 · balance_after: Includes 2,363.3569 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan.

SEC source: 0001209191-23-025692 · doc4.xml · nonDerivative · entry 1

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,803.3569

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 2,363.3569 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan.

SEC source: 0001209191-23-011993 · doc4.xml · nonDerivative · entry 2

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,750.5543

SEC source: 0001209191-23-011993 · doc4.xml · nonDerivative · entry 1

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,982.5543

F1 · kind: On January 29, 2020, the reporting person was granted 6,080 performance share units. The performance share units were eligible to vest based on achievement of a cumulative earnings per share goal for fiscal years 2020-2022. The number of performance share units that were eligible to vest varied from zero (for actual performance less than 90% of target) to two times the units granted (for actual performance of 110% or more of target). Based upon the Company's achievement with respect to cumulative 2020-2022 earnings per share, the number of performance share units that vested equaled 200% of the units granted.

SEC source: 0001209191-23-006031 · doc4.xml · nonDerivative · entry 2

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,822.5543

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $257.1031 to $257.285, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · balance_after: Includes 2,330.5543 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan.

SEC source: 0001209191-23-006031 · doc4.xml · derivative · entry 3

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,524

Underlying: Common Stock · 14,524 shares

Expires 2033-01-30

F3 · derivative.exercise_date: The stock appreciation rights vest in four equal annual installments beginning on January 30, 2024.

SEC source: 0001209191-23-006031 · doc4.xml · nonDerivative · entry 1

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,822.5543

F1 · balance_after: Includes 2,330.5543 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan.

SEC source: 0001209191-22-012404 · doc4.xml · nonDerivative · entry 2

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,143.706

SEC source: 0001209191-22-012404 · doc4.xml · nonDerivative · entry 1

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,801.706

F1 · kind: On January 30, 2019, the reporting person was granted 5,420 performance share units. The performance share units were eligible to vest based on achievement of a cumulative earnings per share goal for fiscal years 2019-2021. The number of performance share units that were eligible to vest varied from zero (for actual performance less than 90% of target) to two times the units granted (for actual performance of 110% or more of target). Based upon the Company's achievement with respect to cumulative 2019-2021 earnings per share, the number of performance share units that vested equaled 200% of the units granted.

SEC source: 0001209191-22-006070 · doc4.xml · derivative · entry 2

Cuffe Michael S. · CIK 0001632835 · EVP and Chief Clinical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,250

Underlying: Common Stock · 15,250 shares

Expires 2032-01-28

F2 · derivative.exercise_date: The stock appreciation rights vest in four equal annual installments beginning on January 28, 2023.

SEC source: 0001209191-21-061840 · doc4.xml · derivative · entry 1

Cuffe Michael S. · CIK 0001632835 · President-Physician Services

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,350

Underlying: Common Stock · 7,350 shares

Expires 2031-10-25

F1 · derivative.exercise_date: The stock appreciation rights vest in four equal annual installments beginning on October 25, 2022.

SEC source: 0001209191-21-050052 · doc4.xml · nonDerivative · entry 1

Cuffe Michael S. · CIK 0001632835 · President-Physician Services

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,914.3007

F1 · balance_after: Includes 2,154.3007 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan.

SEC source: 0001209191-21-029641 · doc4.xml · derivative · entry 4

Cuffe Michael S. · CIK 0001632835 · President-Physician Services

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,930 shares

Expires 2027-02-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock appreciation rights vested in four equal annual installments beginning on February 1, 2018.

SEC source: 0001209191-21-029641 · doc4.xml · nonDerivative · entry 3

Cuffe Michael S. · CIK 0001632835 · President-Physician Services

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,369.3238

F1 · balance_after: Includes 2,109.3238 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan.

SEC source: 0001209191-21-029641 · doc4.xml · nonDerivative · entry 2

Cuffe Michael S. · CIK 0001632835 · President-Physician Services

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,033.3238

F1 · balance_after: Includes 2,109.3238 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan.

SEC source: 0001209191-21-029641 · doc4.xml · nonDerivative · entry 1

Cuffe Michael S. · CIK 0001632835 · President-Physician Services

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,827.3238

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 2,109.3238 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan.

SEC source: 0001209191-21-012992 · doc4.xml · nonDerivative · entry 2

Cuffe Michael S. · CIK 0001632835 · President-Physician Services

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,860.2452

SEC source: 0001209191-21-012992 · doc4.xml · nonDerivative · entry 1

Cuffe Michael S. · CIK 0001632835 · President-Physician Services

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,443.2542

F1 · kind: On January 31, 2018, the reporting person was granted 8,710 performance share units. The performance share units were eligible to vest based on achievement of a cumulative earnings per share goal for fiscal years 2018-2020. The number of performance share units that were eligible to vest varied from zero (for actual performance less than 80% of target) to two times the units granted (for actual performance of 120% or more of target). Based upon the Company's achievement with respect to cumulative 2018-2020 earnings per share, the number of performance share units that vested equaled 162.88% of the units granted.

SEC source: 0001209191-21-008341 · doc4.xml · nonDerivative · entry 5

Cuffe Michael S. · CIK 0001632835 · President-Physician Services

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,257.2542

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.00 to $176.79, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · balance_after: Includes 2,072.2542 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan.

SEC source: 0001209191-21-008341 · doc4.xml · derivative · entry 8

Cuffe Michael S. · CIK 0001632835 · President-Physician Services

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,920

Underlying: Common Stock · 20,920 shares

Expires 2031-02-03

F6 · derivative.exercise_date: The stock appreciation rights vest in four equal annual installments beginning on February 3, 2022.